As the results will be interim results, seems fair to speculate it will not be full results for the full cohort of patients in the 11b being reported in October otherwise it would be the report, not an interim report.
Spot on in quoting the objectives the 11b trial that were dredged up from the FDA site a while ago if memory serves. These facts are directly contrary to hypetastic's claim. The efficacy is being trialled and reported and that is what will have my full attention.
Of course, they need greater numbers than provided by 11b to generate the stats justifying commercialisation, and that is why they do a bigger trial for 111b, but hypetastic why pretend there is no efficacy element to 11b results - that is just nonsense. Where would be the sense in doing 2 safety tests and one massive and expensive efficacy test? It would defy logic and is in any event not true.
Internally, PRR will already have full access to interim, interim reports, lol, and would be expected to act accordingly, so I give some credence to the logic of concluding that 111b is all ahead full because signs are that efficacy result from 11b is going to be good, both interim and final - even if just by a process of elimination - if they were bad, they would not be doing so.
PRR Price at posting:
10.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)